GSK plc GSK NYSE

GSK plc (GSK) generated $2.04B in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $560.25M, free cash flow was $1.48B.

Free cash flow margin was 17.1% of revenue. Cash conversion ratio was 3.24x, indicating earnings are backed by cash.

The company returned $628.49M in dividends to shareholders during the quarter.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (90/100, Pass) — $1.48B (17.1% margin) supports a durable competitive advantage
• INCOME (70/100) — Cash conversion ratio was 3.24x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 64/100 with 4/7 criteria passed.